Preventive effects of influenza and pneumococcal vaccination in the elderly - results from a population-based retrospective cohort study

Hum Vaccin Immunother. 2021 Jun 3;17(6):1844-1852. doi: 10.1080/21645515.2020.1845525. Epub 2021 Jan 7.

Abstract

Influenza and pneumococcal vaccinations are recommended in the elderly to reduce life-threatening complications like sepsis. Protection may be reduced with increasing age. We aimed to assess the effectiveness of both vaccines in the elderly by performing a retrospective cohort study of 138,877 individuals aged ≥60 y in Germany, who were insured in a large statutory health insurance (AOK PLUS). We used longitudinal claims data to classify individuals according to vaccination status 2008-2014, and assessed vaccine effectiveness (VE) in 2015 and 2016. Inverse probability weighting based on generalized propensity scores was used to adjust for systematic between-group differences. Influenza vaccination was associated with a reduction of hospital treatment in laboratory-confirmed influenza in 2015 (VE = 41.32 [95%CI 0.85, 65.26]), but had no significant impact on the overall influenza incidence. Complications of influenza (pneumonia and sepsis) were reduced in 2016. We found a rise in influenza-like illness and acute respiratory infections in both years and an increased 90-d mortality after hospital-treated pneumonia in vaccinees in 2015. Pneumococcal vaccination was effective in preventing hospital-treated pneumonia within the first and second year after vaccination (VE = 52.45 [13.31, 73.92] and 46.04 [5.46, 69.21], respectively), but had no impact on sepsis incidence or pneumonia mortality. Influenza and pneumococcal vaccination can prevent severe complications from influenza and hospital-treated pneumonia in the elderly, respectively. Vaccine effects differ between years and seasons and are partly difficult to interpret. Despite extensive efforts to adjust for between-group differences, residual bias cannot be ruled out, possibly explaining signals like increased ILI or pneumonia mortality.

Keywords: Vaccine effectiveness; influenza; pneumococci; pneumonia; sepsis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cohort Studies
  • Germany
  • Humans
  • Influenza Vaccines*
  • Influenza, Human*
  • Pneumococcal Vaccines
  • Retrospective Studies
  • Vaccination

Substances

  • Influenza Vaccines
  • Pneumococcal Vaccines

Grants and funding

The project vaccination 60+ was funded by German Federal Ministry of Education and Research (BMBF) via InfectControl2020 [FKZ 03ZZ0819A and 03ZZ0819B]. CFS and KR received grants from the German Federal Ministry of Education and Research (BMBF) via the Center for Sepsis Control and Care [CSCC; FKZ: 01EO1002 and 01EO1502]. CF and MWP are partly supported by a grant of the Federal Ministry of Education and Research KliFo 2.0 [grant number 01KI1501]. The funding sources did not influence the design of the study and the writing of the manuscript. They did not influence the collection, analysis, and interpretation of data.